371 related articles for article (PubMed ID: 28984869)
21. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
[No Abstract] [Full Text] [Related]
22. A large fraction of trisomy 12, 17p
Pepe F; Rassenti LZ; Pekarsky Y; Labanowska J; Nakamura T; Nigita G; Kipps TJ; Balatti V; Croce CM
Proc Natl Acad Sci U S A; 2022 Jan; 119(4):. PubMed ID: 35064090
[TBL] [Abstract][Full Text] [Related]
23. Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.
Trends Cancer; 2016 Oct; 2(10):537-539. PubMed ID: 28741484
[No Abstract] [Full Text] [Related]
24. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
[TBL] [Abstract][Full Text] [Related]
25. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
27. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia.
Blombery P; Anderson MA; Gong JN; Thijssen R; Birkinshaw RW; Thompson ER; Teh CE; Nguyen T; Xu Z; Flensburg C; Lew TE; Majewski IJ; Gray DHD; Westerman DA; Tam CS; Seymour JF; Czabotar PE; Huang DCS; Roberts AW
Cancer Discov; 2019 Mar; 9(3):342-353. PubMed ID: 30514704
[TBL] [Abstract][Full Text] [Related]
28. A BH3 Mimetic for Killing Cancer Cells.
Green DR
Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
[TBL] [Abstract][Full Text] [Related]
29. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.
Lucas F; Larkin K; Gregory CT; Orwick S; Doong TJ; Lozanski A; Lozanski G; Misra S; Ngankeu A; Ozer HG; Sampath D; Thangavadivel S; Yilmaz SA; Rogers KA; Byrd JC; Woyach JA; Blachly JS
Blood; 2020 Jun; 135(24):2192-2195. PubMed ID: 32232486
[No Abstract] [Full Text] [Related]
30. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia.
Tam CS; Seymour JF; Roberts AW
Semin Oncol; 2016 Apr; 43(2):274-9. PubMed ID: 27040706
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
Anderson MA; Tam C; Lew TE; Juneja S; Juneja M; Westerman D; Wall M; Lade S; Gorelik A; Huang DCS; Seymour JF; Roberts AW
Blood; 2017 Jun; 129(25):3362-3370. PubMed ID: 28473407
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic development and current uses of BCL-2 inhibition.
Roberts AW
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
34. Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.
Leverson JD; Sampath D; Souers AJ; Rosenberg SH; Fairbrother WJ; Amiot M; Konopleva M; Letai A
Cancer Discov; 2017 Dec; 7(12):1376-1393. PubMed ID: 29146569
[TBL] [Abstract][Full Text] [Related]
35. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
[No Abstract] [Full Text] [Related]
36. Monoallelic and biallelic deletions of 13q14.3 in chronic lymphocytic leukemia: FISH vs miRNA RT-qPCR detection.
Smonskey MT; Block AW; Deeb G; Chanan-Khan AA; Bernstein ZP; Miller KC; Wallace PK; Starostik P
Am J Clin Pathol; 2012 Apr; 137(4):641-6. PubMed ID: 22431542
[TBL] [Abstract][Full Text] [Related]
37. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
Bennett R; Thompson E; Tam C
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
[TBL] [Abstract][Full Text] [Related]
38. Targeting BCL2 for the treatment of lymphoid malignancies.
Anderson MA; Huang D; Roberts A
Semin Hematol; 2014 Jul; 51(3):219-27. PubMed ID: 25048785
[TBL] [Abstract][Full Text] [Related]
39. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax targets BCL2 in chronic lymphocytic leukaemia.
Brower V
Lancet Oncol; 2016 Jan; 17(1):e11. PubMed ID: 26687593
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
